prof. Katrien Vandecasteele (MD, PhD)

CRIG member
KATRIEN VANDECASTEELE


Radiation Oncologist - dept. of radiotherapy - UZ Gent
clinican, principal investigator
50%  mandate for translational en fundamental research - Foundation against Cancer
Professor - dept. of radiotherapy and experimental medicine - Ugent -  (PI: prof. Wilfried De Neve)

 

Research focus

Our team focuses on clinical research in gynaecological cancers, with a strong focus on the multidisciplinary approach of a patient through the establishment of the  GYPON  (Gynaecologisch Pelvien Oncologisch Netwerk). The GYPON is a firm base to perform multidisciplinary based research and the reliability of this group has been proven in the previous and still ongoing multidisciplinary and multi-centric trials. As primary goal we strive for reduced toxicity and a rise in outcome. We have implemented new technologies such as IMRT, SBRT, VMAT in the treatment of gynaecological tumors. We introduced the use of a simultaneously integrated boost and re-introduced surgery in the treatment of locally advanced cervical cancer. Multiple toxicity reducing trials are ongoing or being initiated focusing on radiation induced toxicity such as radiation enteritis, lymph oedema and pelvic insufficiency fractures.
Results of the clinical trials concerning cervical cancer have led a more basic and translational research towards a better understanding of radiation induced cell death and its effects on the tumoral environment and the patients’ immune system. For the latter, I collaborate with the VIB-UGent Inflammation Research Center. 

Biography

  • Intensity Modulated Arc Therapy with simultaneous integrated boost in the treatment for primary irresectable cervical cancer: treatment planning, quality control and clinical implementation. Strahlenther Onkol 2009 (PMID:20013089)
  • Whole abdominopelvic radiotherapy using Intensity Modulated Arc Therapy in the palliative treatment of chemotherapy-resistent ovarian cancer with bulky peritoneal disease: a single institution experience. Int J Radiat Oncol Biol Phys 2011 (PMID:20421155)
  • Intensity Modulated Arc Therapy ± Cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer: toxicity, tumour response, resectability and outcome. Strahlenther Onkol, 2012 (PMID:22526231)
  • Post-operative Intensity-Modulated Arc Therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys. 2012 (PMID:22377596)
  • The value of magnetic resonance in predicting resectability of primary irresectable cervical cancer after treatment with Intensity-Modulated Arc Therapy: a prospective study. Int J Gynecol Cancer. 2012 (PMID:22237382)
  • Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results. Int J Gynecol Cancer; 2013 (PMID:23698797)
  • Immunogenic Apoptotic Cell Death and Anticancer Immunity. Adv Exp Med Biol, 2016 (PMID:27558820)
  • Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology. Oncologist. 2016 (PMID:27009938)
  • TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? Head Neck Pathol 2016 (PMID: 28032290)
  • Incorporating PARP-inhibitors into clinical routine: a tailored treatment strategy to tackle ovarian cancer. Acta Clin Belg, 2017 (PMID:27267353)

 

Contact & links